FORM 6 - K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of 1934
For the month of July 1999
Commission File Number 0-29350
VASOGEN INC.
(Translation of Registrant's name into English)
2155 Dunwin Drive, Suite 10, Mississauga, Ontario, L5L 4M1
(Address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20 - F or Form 40 - F.)
Form 20 - F X Form 40 - F
-------- --------
(Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.)
Yes No X
-------- --------
This Form 6-K consists of:
A press release issued by Vasogen Inc. on July 28, 1999, titled:
"Vasogen Begins Trading on The Toronto Stock Exchange"
SIGNATURE
---------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
VASOGEN INC.
By Christopher Waddick
-----------------------
(Name: Christopher Waddick)
(Title: Vice-President, Finance & CFO)
Date: July 29, 1999
<PAGE>
Vasogen Inc.
INVESTOR CONTACT
2155 Dunwin Drive, Suite 10
Mississauga, ON, Canada L5L 4M1 Trevor Burns
tel (905) 569-2265 fax (905) 569-9231 Investor Relations
http:// www.vasogen.com tel: (905) 569-9065
e-mail: [email protected]
- --------------------------------------------------------------------------------
FOR IMMEDIATE RELEASE
VASOGEN BEGINS TRADING ON THE TORONTO STOCK EXCHANGE
Toronto, Ontario (July 28, 1999) -- Vasogen Inc. (TSE/ME:VAS; NASD OTCBB:VSOGF)
is pleased to announce that, effective July 22, 1999, its common shares began
trading on The Toronto Stock Exchange under the symbol "VAS". In order to
consolidate trading on a single Canadian exchange, the Company will cease
trading on The Montreal Exchange effective July 30, 1999.
Vasogen is developing proprietary immune modulation therapies to advance the
treatment of cardiovascular, autoimmune and related inflammatory diseases. These
therapies are designed to target fundamental disease-causing events,
providing safe, effective treatment.
